Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.

show abstract

“…In a prespecified exploratory analysis of SPARTAN, health-related QOL was maintained in both the apalutamide and placebo groups. 197…”

Section: Apalutamide In M0 Crpcmentioning

confidence: 99%

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Mohler

Antonarakis

Armstrong

et al. 2019

Journal of the National Comprehensive Cancer Network

1,088

841

View full text Add to dashboard Cite

show abstract

“…Averaged research results indicated that apalutamide did not adversely affect HRQQL (physical, social and family, emotional, and functional). A possible decline in HRQQL was caused by the disease progression occurring in both groups [63,83].…”

Section: Apalutamidementioning

confidence: 97%

“…The most common side effects of apalutamide include: Lethargy, hypertension, rashes, diarrhea, nausea, weight loss, arthralgia, falls, hot flashes, bone injury (fracture), decreased appetite, swollen hands, ankles, or feet [78,83].…”

Section: Apalutamidementioning

confidence: 99%

Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer—A Comprehensive Review

et al. 2019

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most common cancers in men that usually develops slowly. Since diagnostic methods improved in the last decade and are highly precise, more cancers are diagnosed at an early stage. Active surveillance or watchful waiting are appealing approaches for men diagnosed with low-risk prostate cancer, and they are an antidote to the overtreatment problem and unnecessary biopsies. However, treatment depends on individual circumstances of a patient. Older hormonal therapies based on first generation antiandrogens and steroids were widely used in metastatic castration-resistant prostate cancer (mCRPC) patients prior to the implementation of docetaxel. Nowadays, accordingly to randomized clinical trials, abiraterone, enzalutamide, apalutamide. and docetaxel became first line agents administrated in the treatment of mCRPC. Furthermore, radium-223 is an optional therapy for bone-only metastasis patients. Sipuleucel-T demonstrated an overall survival benefit. However, other novel immunotherapeutics showed limitations in monotherapy. Possible combinations of new vaccines or immune checkpoint blockers with enzalutamide, abiraterone, radium-223, or docetaxel are the subject of ongoing rivalry regarding optimal therapy of prostate cancer.

show abstract

“…The state-transition probabilities associated with each health state were derived from the literature (Table 1) [2,[17][18][19][20][21][22][23][24]. A time-dependency was implemented for age, meaning that patients were aged 1 year each cycle.…”

Section: Model Structurementioning

confidence: 99%

“…The utilities associated with each health state were derived from the literature (Table 1) [2,[17][18][19][20][21][22][23][24]. Misdiagnosed m0-BCR patients (false positive results of imaging) were attributed the utility score of m1-BCR patients and misdiagnosed m1-BCR patients (false negative results of imaging) entered the model in a tunnel state of one-cycle duration with the same utility as patients in the m0-BCR state.…”

Section: Utilitiesmentioning

confidence: 99%

Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France

et al. 2020

View full text Add to dashboard Cite

Background: The diagnostic performance of 18 F-sodium fluoride positron emission tomography/computed tomography (PET/CT) (NaF), 18 F-fluorocholine PET/CT (FCH) and diffusion-weighted whole-body magnetic resonance imaging (DW-MRI) in detecting bone metastases in prostate cancer (PCa) patients with first biochemical recurrence (BCR) has already been published, but their cost-effectiveness in this indication have never been compared. Methods: We performed trial-based and model-based economic evaluations. In the trial, PCa patients with first BCR after previous definitive treatment were prospectively included. Imaging readings were performed both on-site by local specialists and centrally by experts. The economic evaluation extrapolated the diagnostic performances of the imaging techniques using a combination of a decision tree and Markov model based on the natural history of PCa. The health states were non-metastatic and metastatic BCR, non-metastatic and metastatic castration-resistant prostate cancer and death. The state-transition probabilities and utilities associated with each health state were derived from the literature. Real costs were extracted from the National Cost Study of hospital costs and the social health insurance cost schedule. Results: There was no significant difference in diagnostic performance among the 3 imaging modalities in detecting bone metastases. FCH was the most cost-effective imaging modality above a threshold incremental costeffectiveness ratio of 3000€/QALY when imaging was interpreted by local specialists and 9000€/QALY when imaging was interpreted by experts. Conclusions: FCH had a better incremental effect on QALY, independent of imaging reading and should be preferred for detecting bone metastases in patients with biochemical recurrence of prostate cancer.

show abstract

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

Cited by 115 publications

References 29 publications

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer—A Comprehensive Review

Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France

Contact Info

Product

Resources

About